PURPOSE: BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent BCL2 antagonist and triggers in vitro apoptosis of WM cells. The activity of venetoclax in WM remains to be clarified. PATIENTS AND METHODS: We performed a multicenter, prospective phase II study of venetoclax in patients with previously treated WM (NCT02677324). Venetoclax was dose-escalated from 200 mg to a maximum dose of 800 mg daily for up to 2 years. RESULTS: Thirty-two patients were evaluable, including 16 previously exposed to Bruton tyrosine kinase inhibitors (BTKis). All patients were MYD88 L265P-mutated, and 17 carried CXCR4 mutations. The median time to minor and major responses was 1.9 and 5.1 months, respectively. Previous exposure to BTKis was associated with a longer time to response (4.5 v 1.4 months; P < .001). The overall, major, and very good partial response rates were 84%, 81%, and 19%, respectively. The major response rate was lower in those with refractory versus relapsed disease (50% v 95%; P = .007). The median follow-up time was 33 months, and the median progression-free survival was 30 months. CXCR4 mutations did not affect treatment response or progression-free survival. The only recurring grade ≥ 3 treatment-related adverse event was neutropenia (n = 14; 45%), including one episode of febrile neutropenia. Laboratory tumor lysis without clinical sequelae occurred in one patient. No deaths have occurred. CONCLUSION: Venetoclax is safe and highly active in patients with previously treated WM, including those who previously received BTKis. CXCR4 mutation status did not affect treatment response.
PURPOSE: BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent BCL2 antagonist and triggers in vitro apoptosis of WM cells. The activity of venetoclax in WM remains to be clarified. PATIENTS AND METHODS: We performed a multicenter, prospective phase II study of venetoclax in patients with previously treated WM (NCT02677324). Venetoclax was dose-escalated from 200 mg to a maximum dose of 800 mg daily for up to 2 years. RESULTS: Thirty-two patients were evaluable, including 16 previously exposed to Bruton tyrosine kinase inhibitors (BTKis). All patients were MYD88 L265P-mutated, and 17 carried CXCR4 mutations. The median time to minor and major responses was 1.9 and 5.1 months, respectively. Previous exposure to BTKis was associated with a longer time to response (4.5 v 1.4 months; P < .001). The overall, major, and very good partial response rates were 84%, 81%, and 19%, respectively. The major response rate was lower in those with refractory versus relapsed disease (50% v 95%; P = .007). The median follow-up time was 33 months, and the median progression-free survival was 30 months. CXCR4 mutations did not affect treatment response or progression-free survival. The only recurring grade ≥ 3 treatment-related adverse event was neutropenia (n = 14; 45%), including one episode of febrile neutropenia. Laboratory tumor lysis without clinical sequelae occurred in one patient. No deaths have occurred. CONCLUSION: Venetoclax is safe and highly active in patients with previously treated WM, including those who previously received BTKis. CXCR4 mutation status did not affect treatment response.
Authors: Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter Journal: N Engl J Med Date: 2012-08-30 Impact factor: 91.245
Authors: Constantine S Tam; Mary Ann Anderson; Christiane Pott; Rishu Agarwal; Sasanka Handunnetti; Rodney J Hicks; Kate Burbury; Gillian Turner; Juliana Di Iulio; Mathias Bressel; David Westerman; Stephen Lade; Martin Dreyling; Sarah-Jane Dawson; Mark A Dawson; John F Seymour; Andrew W Roberts Journal: N Engl J Med Date: 2018-03-29 Impact factor: 91.245
Authors: Lian Xu; Zachary R Hunter; Nicholas Tsakmaklis; Yang Cao; Guang Yang; Jie Chen; Xia Liu; Sandra Kanan; Jorge J Castillo; Yu-Tzu Tai; James L Zehnder; Jennifer R Brown; Ruben D Carrasco; Ranjana Advani; Jean M Sabile; Kimon Argyropoulos; M Lia Palomba; Enrica Morra; Alessandra Trojani; Antonino Greco; Alessandra Tedeschi; Marzia Varettoni; Luca Arcaini; Nikhil M Munshi; Kenneth C Anderson; Steven P Treon Journal: Br J Haematol Date: 2015-12-13 Impact factor: 6.998
Authors: Roger G Owen; Robert A Kyle; Marvin J Stone; Andy C Rawstron; Veronique Leblond; Giampaolo Merlini; Ramon Garcia-Sanz; Enrique M Ocio; Enrica Morra; Pierre Morel; Kenneth C Anderson; Christopher J Patterson; Nikhil C Munshi; Alessandra Tedeschi; Douglas E Joshua; Efstathios Kastritis; Evangelos Terpos; Irene M Ghobrial; Xavier Leleu; Morie A Gertz; Stephen M Ansell; William G Morice; Eva Kimby; Steven P Treon Journal: Br J Haematol Date: 2012-11-15 Impact factor: 6.998
Authors: Jorge J Castillo; Ranjana H Advani; Andrew R Branagan; Christian Buske; Meletios A Dimopoulos; Shirley D'Sa; Marie José Kersten; Veronique Leblond; Monique C Minnema; Roger G Owen; M Lia Palomba; Dipti Talaulikar; Alessandra Tedeschi; Judith Trotman; Marzia Varettoni; Josephine M Vos; Steven P Treon; Efstathios Kastritis Journal: Lancet Haematol Date: 2020-11 Impact factor: 18.959
Authors: Anthony R Mato; Lindsey E Roeker; Ryan Jacobs; Brian T Hill; Nicole Lamanna; Danielle Brander; Mazyar Shadman; Chaitra S Ujjani; Maryam Sarraf Yazdy; Guilherme Fleury Perini; Javier A Pinilla-Ibarz; Jacqueline Barrientos; Alan P Skarbnik; Pallawi Torka; Jeffrey J Pu; John M Pagel; Satyen Gohil; Bita Fakhri; Michael Choi; Catherine C Coombs; Joanna Rhodes; Paul M Barr; Craig A Portell; Helen Parry; Christine A Garcia; Kate J Whitaker; Allison M Winter; Andrea Sitlinger; Sirin Khajavian; Ariel F Grajales-Cruz; Krista M Isaac; Pratik Shah; Othman S Akhtar; Rachael Pocock; Kentson Lam; Timothy J Voorhees; Stephen J Schuster; Thomas D Rodgers; Christopher P Fox; Nicolas Martinez-Calle; Talha Munir; Erica B Bhavsar; Neil Bailey; Jason C Lee; Hanna B Weissbrot; Chadi Nabhan; Julie M Goodfriend; Amber C King; Andrew D Zelenetz; Colleen Dorsey; Kayla Bigelow; Bruce D Cheson; John N Allan; Toby A Eyre Journal: Clin Cancer Res Date: 2020-03-20 Impact factor: 12.531
Authors: Steven P Treon; Joshua Gustine; Kirsten Meid; Guang Yang; Lian Xu; Xia Liu; Maria Demos; Amanda Kofides; Nicholas Tsakmaklis; Jiaji G Chen; Manit Munshi; Gloria Chan; Toni Dubeau; Noopur Raje; Andrew Yee; Elizabeth O'Donnell; Zachary R Hunter; Jorge J Castillo Journal: J Clin Oncol Date: 2018-07-25 Impact factor: 44.544
Authors: Steven P Treon; Lian Xu; Maria Luisa Guerrera; Cristina Jimenez; Zachary R Hunter; Xia Liu; Maria Demos; Joshua Gustine; Gloria Chan; Manit Munshi; Nicholas Tsakmaklis; Jiaji G Chen; Amanda Kofides; Romanos Sklavenitis-Pistofidis; Mark Bustoros; Andrew Keezer; Kirsten Meid; Christopher J Patterson; Antonio Sacco; Aldo Roccaro; Andrew R Branagan; Guang Yang; Irene M Ghobrial; Jorge J Castillo Journal: J Clin Oncol Date: 2020-02-21 Impact factor: 44.544